SUNNYVALE, Calif., March 15, 2016 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced CE Mark approval for its next generation ENROUTE Transcarotid Neuroprotection System (NPS). The ENROUTE NPS remains the only device specifically designed and indicated for TransCarotid Artery Revascularization (TCAR), a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.
In partnership with treating physicians and based on feedback from over 700 TCAR procedures, the ENROUTE NPS was enhanced and upgraded to provide physicians with an even more dependable and easy-to-use system to treat their patients in the safest manner possible. The ENROUTE NPS allows the physician to directly access the common carotid artery in the neck and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting Silk Road's ENROUTE® Transcarotid Stent.
The first TCAR procedures with the new ENROUTE NPS were recently performed in leading European hospitals including the Virgen de la Salud Hospital in Toledo, Spain, Klinikum rechts der Isar (Technische Universität München) in Munich, Germany, Augusta Krankenhaus in Dusseldorf Germany, John Paull II Hospital in Krakow, Poland and Gent University Hospital in Gent, Belgium.
Read More: http://www.prnewswire.com/news-releases/silk-road-medical-announces-ce-mark-approval-and-first-patients-treated-with-the-next-generation-enroute-transcarotid-neuroprotection-system-300236473.html
Silk Road Medical Announces CE Mark Approval and First Patients Treated with the Next Generation ENROUTE® Transcarotid Neuroprotection System
Via: PR Newswire